|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
EP3319944A4
(en)
|
2015-07-10 |
2019-04-24 |
Arvinas, Inc. |
MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
|
CN109562113A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的螺环降解决定子体
|
|
CN121974842A
(zh)
|
2016-05-10 |
2026-05-05 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
WO2017197046A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
C3-carbon linked glutarimide degronimers for target protein degradation
|
|
CN109562107A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的杂环降解决定子体
|
|
EP3512842B1
(en)
|
2016-09-15 |
2024-01-17 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
|
MX2019004950A
(es)
|
2016-10-28 |
2019-09-26 |
Icahn School Med Mount Sinai |
Composiciones y metodos para tratar el cancer mediado por el potenciador del homologo zeste 2.
|
|
MX2019005007A
(es)
*
|
2016-11-01 |
2019-07-18 |
Arvinas Inc |
Protac dirigidos a la proteína tau y métodos asociados de uso.
|
|
IL266842B
(en)
|
2016-12-01 |
2022-09-01 |
Arvinas Operations Inc |
History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
|
|
CN110753693A
(zh)
|
2016-12-23 |
2020-02-04 |
阿尔维纳斯运营股份有限公司 |
Egfr蛋白水解靶向嵌合分子和相关使用方法
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
IL325835A
(en)
|
2016-12-23 |
2026-03-01 |
Univ Yale |
Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
IL300417A
(en)
|
2017-01-26 |
2023-04-01 |
Arvinas Operations Inc |
Bifunctional benzothiophene compounds, preparations containing them and their use in therapy
|
|
IL319363A
(en)
|
2017-01-31 |
2025-05-01 |
Arvinas Operations Inc |
Cervalon ligands and bifunctional compounds containing them
|
|
KR102014478B1
(ko)
*
|
2017-05-12 |
2019-08-26 |
한국화학연구원 |
신규한 피페리딘-2,6-디온 유도체 및 이의 용도
|
|
EP4717317A3
(en)
|
2017-06-20 |
2026-06-03 |
C4 Therapeutics, Inc. |
N/o-linked degrons and degronimers for protein degradation
|
|
JP7258009B2
(ja)
|
2017-07-10 |
2023-04-14 |
セルジーン コーポレイション |
抗増殖化合物及びその使用方法
|
|
US20210154184A1
(en)
|
2017-07-12 |
2021-05-27 |
Dana-Farber Cancer Institute, Inc. |
Compounds for tau protein degradation
|
|
WO2019043217A1
(en)
|
2017-09-04 |
2019-03-07 |
F. Hoffmann-La Roche Ag |
DIHYDROBENZIMIDAZOLONES
|
|
WO2019043208A1
(en)
|
2017-09-04 |
2019-03-07 |
F. Hoffmann-La Roche Ag |
DIHYDROQUINOLINONES
|
|
CN118108706A
(zh)
|
2017-09-04 |
2024-05-31 |
C4医药公司 |
戊二酰亚胺
|
|
MX2020003190A
(es)
|
2017-09-22 |
2020-11-11 |
Kymera Therapeutics Inc |
Degradadores de proteinas y usos de los mismos.
|
|
WO2019060693A1
(en)
*
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
EP3710002A4
(en)
|
2017-11-16 |
2021-07-07 |
C4 Therapeutics, Inc. |
DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
|
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
|
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
JP2021512153A
(ja)
|
2018-01-26 |
2021-05-13 |
イエール ユニバーシティ |
タンパク質分解のイミド系モジュレーターおよび使用方法
|
|
WO2019177902A1
(en)
|
2018-03-10 |
2019-09-19 |
Yale University |
Modulators of btk proteolysis and methods of use
|
|
CN111902141A
(zh)
|
2018-03-26 |
2020-11-06 |
C4医药公司 |
用于ikaros降解的羟脑苷脂结合剂
|
|
EP3774804A1
(en)
|
2018-03-26 |
2021-02-17 |
Novartis AG |
N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
|
|
US12539292B2
(en)
|
2018-04-01 |
2026-02-03 |
Arvinas Operations, Inc. |
BRM targeting compounds and associated methods of use
|
|
AU2019249849C1
(en)
|
2018-04-01 |
2022-09-29 |
Arvinas Operations, Inc. |
BRM targeting compounds and associated methods of use
|
|
BR112020020307A2
(pt)
|
2018-04-04 |
2021-01-12 |
Arvinas Operations, Inc. |
Moduladores de proteólise e métodos de uso associados
|
|
CA3095912A1
(en)
*
|
2018-04-13 |
2019-10-17 |
Arvinas Operations, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
WO2019204354A1
(en)
|
2018-04-16 |
2019-10-24 |
C4 Therapeutics, Inc. |
Spirocyclic compounds
|
|
CN118344338A
(zh)
|
2018-04-23 |
2024-07-16 |
细胞基因公司 |
取代的4-氨基异吲哚啉-1,3-二酮化合物以及它们用于治疗淋巴瘤的用途
|
|
BR112020023136A2
(pt)
|
2018-05-14 |
2021-02-09 |
Nuvation Bio Inc. |
compostos de alvo de receptor de hormônio nuclear anticâncer
|
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
|
CA3102212A1
(en)
*
|
2018-06-29 |
2020-01-02 |
Dana-Farber Cancer Institute, Inc. |
Immunomodulatory compounds
|
|
EP3814380A4
(en)
*
|
2018-06-29 |
2022-06-15 |
Dana Farber Cancer Institute, Inc. |
BISPECIFIC DEGRADATION PRODUCTS
|
|
WO2020010204A1
(en)
|
2018-07-05 |
2020-01-09 |
Icahn School Of Medicine At Mount Sinai |
Protein tyrosine kinase 6 (ptk6) degradation / disruption compounds and methods of use
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
US12454520B2
(en)
|
2018-07-06 |
2025-10-28 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
BR122022012697B1
(pt)
|
2018-07-10 |
2023-04-04 |
Novartis Ag |
Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
US20200038513A1
(en)
|
2018-07-26 |
2020-02-06 |
Arvinas Operations, Inc. |
Modulators of fak proteolysis and associated methods of use
|
|
WO2020027225A1
(ja)
|
2018-07-31 |
2020-02-06 |
ファイメクス株式会社 |
複素環化合物
|
|
CN108774215A
(zh)
*
|
2018-08-15 |
2018-11-09 |
翟学旭 |
含氮杂环类衍生物及其在视网膜新生血管疾病中的应用
|
|
US11707452B2
(en)
|
2018-08-20 |
2023-07-25 |
Arvinas Operations, Inc. |
Modulators of alpha-synuclein proteolysis and associated methods of use
|
|
US11969472B2
(en)
|
2018-08-22 |
2024-04-30 |
Cullgen (Shanghai), Inc. |
Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
|
|
MX2021001957A
(es)
|
2018-08-22 |
2021-07-15 |
Cullgen Shanghai Inc |
Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk).
|
|
WO2020051235A1
(en)
|
2018-09-04 |
2020-03-12 |
C4 Therapeutics, Inc. |
Compounds for the degradation of brd9 or mth1
|
|
US11319330B2
(en)
*
|
2018-09-07 |
2022-05-03 |
Medshine Discovery Inc. |
Tricyclic furan-substituted piperidinedione compound
|
|
AU2019389174A1
(en)
|
2018-11-30 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
CN113490495B
(zh)
*
|
2018-12-03 |
2024-09-27 |
达纳-法伯癌症研究公司 |
Helios的小分子降解剂及其使用方法
|
|
AU2019404022A1
(en)
|
2018-12-19 |
2021-07-08 |
Celgene Corporation |
Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
|
|
BR112021011968A2
(pt)
|
2018-12-19 |
2021-09-08 |
Celgene Corporation |
Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos
|
|
EP3897631A4
(en)
|
2018-12-20 |
2022-11-23 |
C4 Therapeutics, Inc. |
TARGETED PROTEIN BREAKDOWN
|
|
WO2020160295A1
(en)
*
|
2019-01-30 |
2020-08-06 |
Montelino Therapeutics, Llc |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
|
KR102876423B1
(ko)
*
|
2019-02-07 |
2025-10-24 |
한국화학연구원 |
표적 단백질 ｅｅｄ 분해 유도 데그라듀서, 이의 제조방법 및 이를 유효성분으로 함유하는 ｅｅｄ, ｅｚｈ2, 또는 ｐｒｃ2 관련 질환의 예방 또는 치료용 약학적 조성물
|
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US20220143183A1
(en)
*
|
2019-02-23 |
2022-05-12 |
New York University |
Photoswitchable protacs and synthesis and uses thereof
|
|
ES2995214T3
(en)
|
2019-03-06 |
2025-02-07 |
C4 Therapeutics Inc |
Heterocyclic compounds for medical treatment
|
|
KR102980990B1
(ko)
|
2019-04-05 |
2026-06-25 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Stat 분해제 및 이의 용도
|
|
WO2020206608A1
(en)
*
|
2019-04-09 |
2020-10-15 |
Ranok Therapeutics (Hangzhou) Co., Ltd. |
Methods and compositions for targeted protein degradation
|
|
WO2020214555A1
(en)
|
2019-04-16 |
2020-10-22 |
Northwestern University |
Bifunctional compounds comprising apcin-a and their use in the treatment of cancer
|
|
BR112021020775A2
(pt)
*
|
2019-04-18 |
2021-12-14 |
Hinova Pharmaceuticals Inc |
Classe de compostos heterocíclicos quiméricos bifuncionais para a degradação direcionada de receptores de andrógeno e uso dos mesmos
|
|
CN114423463B
(zh)
*
|
2019-05-06 |
2025-09-26 |
西奈山伊坎医学院 |
作为hpk1的降解剂的异双功能化合物
|
|
CN113811333B
(zh)
|
2019-05-14 |
2024-03-12 |
诺维逊生物股份有限公司 |
靶向抗癌核激素受体的化合物
|
|
US20230087825A1
(en)
*
|
2019-06-10 |
2023-03-23 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
US12624044B2
(en)
|
2019-06-10 |
2026-05-12 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
WO2020251972A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
WO2020252397A1
(en)
*
|
2019-06-12 |
2020-12-17 |
Baylor College Of Medicine |
Small molecule proteolysis-targeting chimeras and methods of use thereof
|
|
CN114245807B
(zh)
|
2019-06-25 |
2025-05-02 |
吉利德科学公司 |
Flt3l-fc融合蛋白和使用方法
|
|
PH12022500002A1
(en)
|
2019-06-28 |
2023-04-03 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
EP3999182A1
(en)
|
2019-07-17 |
2022-05-25 |
Arvinas Operations, Inc. |
Tau-protein targeting compounds and associated methods of use
|
|
US12558427B2
(en)
|
2019-07-17 |
2026-02-24 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
WO2021041348A1
(en)
*
|
2019-08-26 |
2021-03-04 |
Arvinas Operations, Inc. |
Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
|
|
AU2020336381A1
(en)
*
|
2019-08-27 |
2022-03-03 |
The Regents Of The University Of Michigan |
Cereblon E3 ligase inhibitors
|
|
JP7209897B2
(ja)
*
|
2019-09-12 |
2023-01-20 |
メッドシャイン ディスカバリー インコーポレイテッド |
Ｃｒｂｎタンパク質モジュレーターとしての二環式化合物
|
|
TW202123942A
(zh)
*
|
2019-09-16 |
2021-07-01 |
瑞士商諾華公司 |
Ｂｒｄ９雙官能基降解劑及其使用方法
|
|
JP7874541B2
(ja)
*
|
2019-09-16 |
2026-06-16 |
ノバルティス アーゲー |
接着分解剤及びその使用方法
|
|
JP7502425B2
(ja)
|
2019-10-01 |
2024-06-18 |
アルヴィナス・オペレーションズ・インコーポレイテッド |
Ｂｒｍ標的化化合物および関連使用方法
|
|
MX2022004526A
(es)
|
2019-10-17 |
2022-07-21 |
Arvinas Operations Inc |
Moléculas bifuncionales que contienen una porción de unión a la ligasa de ubiquitina e3 unida a una porción de direccionamiento a bcl6.
|
|
EP4058464A1
(en)
|
2019-11-13 |
2022-09-21 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
CN110885332B
(zh)
*
|
2019-12-06 |
2022-03-18 |
中国人民解放军第二军医大学 |
一种PDEδ蛋白降解靶向嵌合体及其制备方法和应用
|
|
WO2021119159A1
(en)
|
2019-12-10 |
2021-06-17 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
GB201918414D0
(en)
|
2019-12-13 |
2020-01-29 |
Z Factor Ltd |
Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
|
|
CA3162252A1
(en)
|
2019-12-17 |
2021-06-24 |
Nikolai Kley |
Modulation of protein degradation
|
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
|
CA3161878A1
(en)
|
2019-12-17 |
2021-06-24 |
Matthew M. Weiss |
Irak degraders and uses thereof
|
|
WO2021127443A1
(en)
|
2019-12-19 |
2021-06-24 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
EP4681715A3
(en)
|
2019-12-20 |
2026-01-28 |
C4 Therapeutics, Inc. |
Isoindolinone and indazole compounds for the degradation of egfr
|
|
AU2020414151A1
(en)
|
2019-12-23 |
2022-08-25 |
Jiangxi Jemincare Group Co., Ltd |
Protein degradation agent compound preparation method and application
|
|
US11679109B2
(en)
|
2019-12-23 |
2023-06-20 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
WO2021133917A1
(en)
|
2019-12-23 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Smarca inhibitors and uses thereof
|
|
EP4090371A4
(en)
*
|
2020-01-14 |
2024-04-03 |
The Trustees of Columbia University in the City of New York |
COMPOSITIONS AND METHODS FOR TARGETED PROTEIN STABILIZATION BY RE-ROUTING ENDOGENOUS DEUBIQUITINASES
|
|
TW202140475A
(zh)
*
|
2020-01-16 |
2021-11-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
稠合醯亞胺類衍生物、其製備方法及其在醫藥上的應用
|
|
WO2021143822A1
(zh)
*
|
2020-01-16 |
2021-07-22 |
江苏恒瑞医药股份有限公司 |
并环酰亚胺类衍生物、其制备方法及其在医药上的应用
|
|
US11618751B1
(en)
|
2022-03-25 |
2023-04-04 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
|
|
TWI890283B
(zh)
|
2020-02-14 |
2025-07-11 |
美商基利科學股份有限公司 |
結合ccr8之抗體及融合蛋白及其用途
|
|
JP7815127B2
(ja)
|
2020-02-19 |
2026-02-17 |
ニューリックス セラピューティクス，インコーポレイテッド |
インターロイキン－１受容体関連キナーゼの二機能性分解剤およびその治療的使用
|
|
BR112022016901A2
(pt)
|
2020-02-26 |
2022-12-06 |
Cullgen Shanghai Inc |
Compostos de degradação do receptor de tropomiosina quinase (trk) e métodos de uso
|
|
EP3875456A1
(en)
*
|
2020-03-02 |
2021-09-08 |
Technische Universität Darmstadt |
Hetero-bifunctional proteolysis-targeting chimeras (protacs) for the selective degradation of fk506-binding proteins (fkbps)
|
|
CN119823124A
(zh)
|
2020-03-05 |
2025-04-15 |
C4医药公司 |
用于brd9的靶向降解的化合物
|
|
CN111249276B
(zh)
*
|
2020-03-05 |
2021-07-13 |
南京巴傲得生物科技有限公司 |
吲哚布洛芬制备cbp溴区抑制试剂的用途
|
|
CA3170620A1
(en)
*
|
2020-03-06 |
2021-09-10 |
Maoyi LEI |
Crystal of tricyclic compound acting on crbn protein and preparation method therefor
|
|
CN113387931A
(zh)
*
|
2020-03-13 |
2021-09-14 |
四川海思科制药有限公司 |
一种具有抑制或降解蛋白激酶的化合物及其制备方法和药学上的应用
|
|
CN115380026B
(zh)
*
|
2020-03-17 |
2023-11-07 |
南京明德新药研发有限公司 |
蛋白降解调节剂与其使用方法
|
|
EP4121046A4
(en)
*
|
2020-03-18 |
2024-04-24 |
Dana-Farber Cancer Institute, Inc. |
Targeted degraders of aberrant tau based on the pet tracer pbb3
|
|
WO2021188948A1
(en)
|
2020-03-19 |
2021-09-23 |
Kymera Therapeutics, Inc. |
Mdm2 degraders and uses thereof
|
|
US20230158158A1
(en)
*
|
2020-03-27 |
2023-05-25 |
Uppthera |
Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1
|
|
WO2021210878A1
(ko)
*
|
2020-04-17 |
2021-10-21 |
광주과학기술원 |
Crbn 결합 펩티드 및 이를 이용한 알츠하이머 병 예방 또는 치료용 조성물
|
|
WO2021219077A1
(zh)
*
|
2020-04-29 |
2021-11-04 |
泰比棣医药科技(石家庄)有限公司 |
一种组织靶向的蛋白靶向降解化合物及其用途
|
|
CN113582974B
(zh)
*
|
2020-04-30 |
2022-05-17 |
江西济民可信集团有限公司 |
一类作为蛋白降解剂的化合物及其制备方法和医药用途
|
|
WO2021231927A1
(en)
*
|
2020-05-14 |
2021-11-18 |
The Regents Of The University Of Michigan |
Androgen receptor protein degraders with a tricyclic cereblon ligand
|
|
US20230192644A1
(en)
*
|
2020-05-21 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Piperidine-2,6-diones as small molecule degraders of helios and methods of use
|
|
EP4161521A4
(en)
|
2020-06-03 |
2024-07-10 |
Kymera Therapeutics, Inc. |
DEUTERED IRAQ DEGRADERS AND USES THEREOF
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
KR20230024328A
(ko)
|
2020-06-12 |
2023-02-20 |
상하이 제민케어 파마슈티칼스 컴퍼니 리미티드 |
프탈라지논 화합물, 이의 제조 방법 및 이의 의학적 용도
|
|
WO2021255212A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Braf degraders
|
|
AU2021296165A1
(en)
*
|
2020-06-22 |
2022-11-24 |
Dana-Farber Cancer Institute, Inc. |
Protein tag to induce ligand dependent degradation of protein/protein-fusions
|
|
KR102559329B1
(ko)
*
|
2020-07-02 |
2023-07-25 |
포항공과대학교 산학협력단 |
신규한 프로탁 키메라 화합물, 이를 포함하는 표적 단백질 분해를 통한 질환의 예방, 개선 또는 치료용 약학적 조성물
|
|
TW202216684A
(zh)
*
|
2020-07-09 |
2022-05-01 |
大陸商四川海思科製藥有限公司 |
用於抑制與降解雄激素受體的化合物、醫藥組合物及其應用
|
|
WO2022019597A1
(ko)
*
|
2020-07-21 |
2022-01-27 |
주식회사 유빅스테라퓨틱스 |
안드로겐 수용체 분해용 화합물 및 이들의 의약 용도
|
|
WO2022025640A1
(ko)
*
|
2020-07-29 |
2022-02-03 |
한국화학연구원 |
안드로겐 수용체의 저해 또는 분해용 화합물 및 이들의 의약 용도
|
|
AU2021319847A1
(en)
*
|
2020-08-03 |
2023-03-02 |
Captor Therapeutics S.A. |
Low molecular weight protein degraders and their applications
|
|
CN117964623A
(zh)
*
|
2020-08-05 |
2024-05-03 |
上海领泰生物医药科技有限公司 |
靶向蛋白降解化合物及其制备方法和应用
|
|
CN116490186B
(zh)
|
2020-08-05 |
2025-10-31 |
C4医药公司 |
用于ret的靶向降解的化合物
|
|
WO2022047145A1
(en)
|
2020-08-28 |
2022-03-03 |
Arvinas Operations, Inc. |
Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
|
|
WO2022048605A1
(zh)
*
|
2020-09-04 |
2022-03-10 |
南昌奥瑞药业有限公司 |
一种杂环化合物、其制备方法、中间体、组合物以及应用
|
|
CN114163444B
(zh)
*
|
2020-09-11 |
2023-07-14 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
AU2021342287A1
(en)
|
2020-09-14 |
2023-04-13 |
Arvinas Operations, Inc. |
Crystalline forms of a compound for the targeted degradation of estrogen receptor
|
|
CN114181277A
(zh)
*
|
2020-09-15 |
2022-03-15 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
WO2022066835A1
(en)
|
2020-09-23 |
2022-03-31 |
St. Jude Children's Research Hospital, Inc. |
Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein
|
|
PE20230782A1
(es)
*
|
2020-09-30 |
2023-05-09 |
Astrazeneca Ab |
Compuestos y su uso en el tratamiento del cancer
|
|
CA3194351A1
(en)
*
|
2020-10-14 |
2022-04-21 |
Christopher G. Nasveschuk |
Tricyclic compounds to degrade neosubstrates for medical therapy
|
|
WO2022087125A1
(en)
|
2020-10-21 |
2022-04-28 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor protein
|
|
US12606568B2
(en)
|
2020-12-09 |
2026-04-21 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
|
CN114621231B
(zh)
*
|
2020-12-14 |
2025-09-12 |
杭州中美华东制药有限公司 |
一种靶向降解/抑制活性的嵌合化合物及其制备方法和用途
|
|
AR124547A1
(es)
|
2020-12-30 |
2023-04-05 |
Kymera Therapeutics Inc |
Degradadores de irak y sus usos
|
|
CN117242060B
(zh)
|
2021-01-13 |
2026-07-17 |
蒙特罗莎治疗股份有限公司 |
异吲哚啉酮化合物
|
|
US12655135B2
(en)
|
2021-02-04 |
2026-06-16 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Benzo seven-membered ring bifunctional compound and application thereof
|
|
MX2023009178A
(es)
|
2021-02-15 |
2023-08-21 |
Kymera Therapeutics Inc |
Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
|
|
WO2022174268A1
(en)
|
2021-02-15 |
2022-08-18 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
EP4294790A4
(en)
*
|
2021-02-19 |
2025-02-26 |
Kymera Therapeutics, Inc. |
SMARCA DEGRADING AGENTS AND RELATED USES
|
|
WO2022183006A1
(en)
|
2021-02-25 |
2022-09-01 |
Mayo Foundation For Medical Education And Research |
Compounds for programmable protein degradation and methods of use for the disease treatment
|
|
EP4308559A1
(en)
*
|
2021-03-15 |
2024-01-24 |
Novartis AG |
Benzisoxazole derivatives and uses thereof
|
|
CN116940571A
(zh)
*
|
2021-03-15 |
2023-10-24 |
诺华股份有限公司 |
苯并异噁唑衍生物及其用途
|
|
EP4313991A1
(en)
|
2021-03-23 |
2024-02-07 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
JP2024512544A
(ja)
*
|
2021-03-29 |
2024-03-19 |
江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 |
テトラヒドロナフタレン系化合物、その製造方法及びその医薬的応用
|
|
CN115141179B
(zh)
*
|
2021-03-31 |
2024-09-13 |
江苏恒瑞医药股份有限公司 |
一种新型苯并杂环基类衍生物、其制备方法及其在医药上的应用
|
|
MX2023011378A
(es)
*
|
2021-03-31 |
2023-10-06 |
Duke Street Bio Ltd |
Compuesto farmaceutico.
|
|
US11319319B1
(en)
|
2021-04-07 |
2022-05-03 |
Ventus Therapeutics U.S., Inc. |
Compounds for inhibiting NLRP3 and uses thereof
|
|
CN118388454A
(zh)
|
2021-04-16 |
2024-07-26 |
阿尔维纳斯运营股份有限公司 |
Bcl6蛋白水解的调节剂和其相关使用方法
|
|
CN113603676B
(zh)
*
|
2021-04-28 |
2022-05-24 |
浙江工业大学 |
基于厄洛替尼靶向降解egfr蛋白小分子化合物及其制备方法和应用
|
|
WO2022235585A1
(en)
*
|
2021-05-03 |
2022-11-10 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
US20240287076A1
(en)
|
2021-05-05 |
2024-08-29 |
Biogen Ma Inc. |
Compounds for targeting degradation of bruton's tyrosine kinase
|
|
CA3217792A1
(en)
|
2021-05-07 |
2022-11-10 |
Kymera Therapeutics, Inc |
Cdk2 degraders and uses thereof
|
|
WO2022245671A1
(en)
|
2021-05-18 |
2022-11-24 |
Gilead Sciences, Inc. |
Methods of using flt3l-fc fusion proteins
|
|
JP2024519628A
(ja)
*
|
2021-05-26 |
2024-05-21 |
イノキュア セラピューティクス インコーポレイテッド |
ピペリジンジオン誘導体
|
|
WO2022250350A1
(ko)
*
|
2021-05-26 |
2022-12-01 |
주식회사 이노큐어테라퓨틱스 |
피페리딘디온 유도체
|
|
KR102489160B1
(ko)
*
|
2021-05-26 |
2023-01-18 |
주식회사 이노큐어테라퓨틱스 |
피페리딘디온 유도체
|
|
KR102474999B1
(ko)
*
|
2021-05-26 |
2022-12-07 |
주식회사 이노큐어테라퓨틱스 |
피페리딘디온 유도체
|
|
BR112023024507A2
(pt)
|
2021-05-26 |
2024-02-15 |
C4 Therapeutics Inc |
Método para tratar um câncer mediado por receptor do fator de crescimento epidérmico mutante que sofreu metástase para o cérebro ou sistema nervoso central
|
|
WO2022255888A1
(en)
*
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
|
|
WO2022255889A1
(en)
*
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Compounds which bind to cereblon, and use thereof
|
|
WO2022255890A1
(en)
*
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Compounds which bind to cereblon, and use thereof
|
|
AU2022290851A1
(en)
|
2021-06-08 |
2023-11-23 |
C4 Therapeutics, Inc. |
Therapeutics for the degradation of mutant braf
|
|
KR20240026946A
(ko)
*
|
2021-06-25 |
2024-02-29 |
셀진 코포레이션 |
세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
|
|
EP4359404A4
(en)
*
|
2021-06-25 |
2025-06-04 |
Celgene Corporation |
Cereblon-binding compounds, compositions thereof and methods of treatment therewith
|
|
KR20240026939A
(ko)
*
|
2021-06-25 |
2024-02-29 |
셀진 코포레이션 |
세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
|
|
US20250129047A1
(en)
|
2021-07-04 |
2025-04-24 |
Newave Pharmaceutical Inc. |
Isoquinoline derivatives as mutant egfr modulators and uses thereof
|
|
WO2023283372A1
(en)
|
2021-07-07 |
2023-01-12 |
Biogen Ma Inc. |
Compounds for targeting degradation of irak4 proteins
|
|
CA3224732A1
(en)
|
2021-07-07 |
2023-01-12 |
Kevin M. Guckian |
Compounds for targeting degradation of irak4 proteins
|
|
TW202317546A
(zh)
|
2021-07-09 |
2023-05-01 |
美商普萊克斯姆公司 |
調節ikzf2之芳基化合物及醫藥組合物
|
|
JP7555155B2
(ja)
*
|
2021-08-10 |
2024-09-24 |
オップテラ インコーポレイテッド |
新規ｐｌｋ１分解誘導化合物
|
|
WO2023016518A1
(zh)
*
|
2021-08-11 |
2023-02-16 |
四川海思科制药有限公司 |
一种杂环衍生物及其组合物和药学上的应用
|
|
HUE070709T2
(hu)
|
2021-08-18 |
2025-06-28 |
Nurix Therapeutics Inc |
Interleukin-1 receptorhoz kapcsolódó kinázok kétfunkciós lebontói és terápiás alkalmazásuk
|
|
EP4393922A4
(en)
*
|
2021-08-23 |
2026-01-28 |
Leadingtac Pharmaceutical Shaoxing Co Ltd |
IRAK4 DEGRADATION AGENT, ITS PREPARATION PROCESS AND ITS USE
|
|
EP4395549A1
(en)
|
2021-09-01 |
2024-07-10 |
Oerth Bio LLC |
Compositions and methods for targeted degradation of proteins in a plant cell
|
|
CN115746058A
(zh)
*
|
2021-09-03 |
2023-03-07 |
南京知和医药科技有限公司 |
一种多环化合物在制备抗肿瘤药物方面的用途
|
|
WO2023056443A1
(en)
*
|
2021-10-01 |
2023-04-06 |
Dana-Farber Cancer Institute, Inc. |
Binders of cereblon and methods of use thereof
|
|
WO2023059792A1
(en)
*
|
2021-10-06 |
2023-04-13 |
C4 Thrapeutics, Inc. |
Coronavirus non-structural protein 3 degrading compounds
|
|
JP2024539269A
(ja)
*
|
2021-10-22 |
2024-10-28 |
グルータクス セラピューティクス （シャンハイ） カンパニー、リミテッド |
Ｃｒｂｎ ｅ３リガーゼリガンド化合物、当該リガンド化合物に基づいて開発したタンパク質分解剤及びそれらの応用
|
|
EP4423078A1
(en)
|
2021-10-28 |
2024-09-04 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
JP2024540080A
(ja)
|
2021-10-29 |
2024-10-31 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ４分解剤およびその合成
|
|
PE20241186A1
(es)
|
2021-10-29 |
2024-06-03 |
Gilead Sciences Inc |
Compuestos de cd73
|
|
US20250122166A1
(en)
*
|
2021-11-03 |
2025-04-17 |
St. Jude Children's Research Hospital, Inc. |
Substituted n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)methyl)benzamide analogs as modulators of cereblon protein
|
|
WO2023081452A1
(en)
*
|
2021-11-05 |
2023-05-11 |
University Of South Carolina |
Small-molecule degraders of cdk8 and cdk19
|
|
CN119823111B
(zh)
*
|
2021-11-18 |
2026-05-05 |
正大天晴药业集团股份有限公司 |
稠合酰亚胺类衍生物
|
|
JP2024541479A
(ja)
|
2021-11-24 |
2024-11-08 |
アルビナス・オペレーションズ・インコーポレイテッド |
Ｂｒｍ標的化化合物及び関連使用方法
|
|
CN118679160A
(zh)
|
2021-11-24 |
2024-09-20 |
阿维纳斯运营公司 |
Brm靶向化合物和相关的使用方法
|
|
WO2023093845A1
(zh)
|
2021-11-25 |
2023-06-01 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
CN118488948A
(zh)
|
2021-12-22 |
2024-08-13 |
吉利德科学公司 |
Ikaros锌指家族降解剂及其用途
|
|
US20240124412A1
(en)
|
2021-12-22 |
2024-04-18 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
CN114085213B
(zh)
*
|
2022-01-20 |
2022-03-25 |
苏州国匡医药科技有限公司 |
一种arv-471的制备方法
|
|
CA3248911A1
(en)
|
2022-01-28 |
2023-08-03 |
Gilead Sciences, Inc. |
POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
|
|
EP4472967A4
(en)
|
2022-01-31 |
2026-04-15 |
Kymera Therapeutics Inc |
Iraqi Degradation Agents and Their Uses
|
|
PL4245756T3
(pl)
|
2022-03-17 |
2025-02-17 |
Gilead Sciences, Inc. |
Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
|
|
CN119301111A
(zh)
*
|
2022-03-24 |
2025-01-10 |
葛兰素史密斯克莱知识产权发展有限公司 |
作为protac中的降解决定子的2,4-二氧代四氢嘧啶基衍生物
|
|
EP4511128A1
(en)
|
2022-04-20 |
2025-02-26 |
Kumquat Biosciences Inc. |
Macrocyclic heterocycles and uses thereof
|
|
EP4511127A1
(en)
|
2022-04-21 |
2025-02-26 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2023212599A2
(en)
*
|
2022-04-26 |
2023-11-02 |
Endotarget Inc. |
Compounds and methods for targeted degradation of estrogen receptors
|
|
IL316803A
(en)
|
2022-06-06 |
2025-01-01 |
C4 Therapeutics Inc |
Bicyclic glutarimide-modified cervalon-binding agents
|
|
WO2024002205A1
(en)
*
|
2022-06-30 |
2024-01-04 |
Anhorn Medicines Co., Ltd. |
Bifunctional compound and pharmaceutical composition comprising the bifunctional compound, and method for treating androgen receptor related disease by using the same
|
|
WO2024006929A1
(en)
|
2022-07-01 |
2024-01-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
EP4554948A1
(en)
*
|
2022-07-12 |
2025-05-21 |
Regents of the University of Michigan |
Tetrahydronaphthalene derivatives as estrogen receptor degraders
|
|
CN116496253B
(zh)
*
|
2022-08-19 |
2024-10-11 |
中国人民解放军军事科学院军事医学研究院 |
c-MET蛋白靶向降解剂及其医药应用
|
|
CN115089588A
(zh)
*
|
2022-08-22 |
2022-09-23 |
云南大学 |
达沙布韦作为e3连接酶新型配体构建protac的应用
|
|
WO2024050016A1
(en)
|
2022-08-31 |
2024-03-07 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
EP4584258A1
(en)
|
2022-09-07 |
2025-07-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
|
WO2024054954A1
(en)
*
|
2022-09-08 |
2024-03-14 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
CN118019736A
(zh)
*
|
2022-09-08 |
2024-05-10 |
标新生物医药科技(上海)有限公司 |
基于cereblon蛋白设计的分子胶化合物及其应用
|
|
US20260159520A1
(en)
*
|
2022-09-08 |
2026-06-11 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
US20250388575A1
(en)
*
|
2022-09-08 |
2025-12-25 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
JP2025531869A
(ja)
|
2022-09-09 |
2025-09-25 |
イノヴォ セラピューティクス、インコーポレイテッド |
ＣＫ１αおよびＤＵＡＬ ＣＫ１α／ＧＳＰＴ１分解化合物
|
|
CN119855812A
(zh)
*
|
2022-09-14 |
2025-04-18 |
海南先声再明医药股份有限公司 |
多并环类化合物及其用途
|
|
WO2024064316A1
(en)
|
2022-09-23 |
2024-03-28 |
Regents Of The University Of Michigan |
Compounds and compositions as smarca2/4 inhibitors and uses thereof
|
|
WO2024073475A1
(en)
*
|
2022-09-27 |
2024-04-04 |
Oncopia Therapeutics, Inc. D/B/A Proteovant Therapeutics, Inc. |
Cereblon ligands and uses thereof
|
|
CN119998300A
(zh)
*
|
2022-09-29 |
2025-05-13 |
海南先声再明医药股份有限公司 |
一类稠环化合物及其用途
|
|
JP2025533592A
(ja)
*
|
2022-09-29 |
2025-10-07 |
江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 |
テトラリン系誘導体の薬学的に許容される塩、結晶型及び調製方法
|
|
CN117801051A
(zh)
*
|
2022-09-30 |
2024-04-02 |
苏州德亘生物医药有限公司 |
一类eRF3a靶向蛋白降解机制治疗人类肿瘤的药物
|
|
EP4608404A1
(en)
|
2022-10-24 |
2025-09-03 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
US12331048B2
(en)
|
2022-10-31 |
2025-06-17 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
|
|
EP4624472A1
(en)
*
|
2022-11-22 |
2025-10-01 |
Innocure Therapeutics, Inc. |
Degrader including novel c-met protein ligand and pharmaceutical composition including same
|
|
EP4624466A1
(en)
*
|
2022-11-22 |
2025-10-01 |
Innocure Therapeutics, Inc. |
Degrader for decomposing cmet protein, and pharmaceutical composition comprising same
|
|
JP2025538554A
(ja)
*
|
2022-11-22 |
2025-11-28 |
イノキュア セラピューティクス，インコーポレイテッド |
Ｂｒｄタンパク質を分解するための分解剤およびそれを含有する薬学的組成物
|
|
WO2024123195A1
(en)
*
|
2022-12-06 |
2024-06-13 |
Captor Therapeutics S.A. |
Targeted protein degradation using prodrugs of bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
|
|
JP2025540970A
(ja)
*
|
2022-12-06 |
2025-12-17 |
キャプター セラピューティクス エス．エー． |
ユビキチンリガーゼ及びターゲットｍｃｌ－１タンパク質に結合する二機能性化合物を使用するターゲティングされたタンパク質分解
|
|
EP4638436A1
(en)
|
2022-12-22 |
2025-10-29 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
CN120615091A
(zh)
*
|
2023-01-16 |
2025-09-09 |
正大天晴药业集团股份有限公司 |
取代的苯并七元环化合物及其应用
|
|
PE20260006A1
(es)
|
2023-01-26 |
2026-01-06 |
Arvinas Operations Inc |
Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
|
|
US20260232673A1
(en)
*
|
2023-02-16 |
2026-08-13 |
Bristol-Myers Squibb Company |
Isoindolinone glutarimide and phenyl glutarimide analogs as degraders of ret kinase
|
|
CN116253719B
(zh)
*
|
2023-03-06 |
2025-04-01 |
苏州国匡医药科技有限公司 |
一种雌激素和雄激素受体双重降解剂及其应用
|
|
US20240374588A1
(en)
|
2023-04-07 |
2024-11-14 |
Astrazeneca Ab |
Irak4 protacs
|
|
WO2024215754A1
(en)
|
2023-04-11 |
2024-10-17 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
KR20250173569A
(ko)
*
|
2023-04-20 |
2025-12-10 |
오론 세러퓨틱스 인코포레이티드 |
세포 상태 표적화 기술
|
|
PE20260121A1
(es)
|
2023-04-21 |
2026-01-16 |
Gilead Sciences Inc |
Inhibidores de prmt5 y usos de los mismos
|
|
WO2024243441A1
(en)
|
2023-05-24 |
2024-11-28 |
Kumquat Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
EP4722207A1
(en)
*
|
2023-06-01 |
2026-04-08 |
Gluetacs Therapeutics (Shanghai) Co., Ltd. |
Oxoisoindolinyl-substituted tetrahydropyrimidinedione derivative and use thereof
|
|
WO2024245443A1
(zh)
*
|
2023-06-01 |
2024-12-05 |
标新生物医药科技(上海)有限公司 |
基于氧代异吲哚啉基取代的四氢嘧啶二酮的化合物及其应用
|
|
CN121263412A
(zh)
*
|
2023-06-01 |
2026-01-02 |
上海海和药物研究开发股份有限公司 |
用于雄激素受体依赖性疾病的苯并(杂)环烷基化合物
|
|
IL325247A
(en)
|
2023-06-14 |
2026-02-01 |
Astrazeneca Ab |
History of 3-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]-8,3-diazabicyclo[3.2.1]octane as a protacs from SMARCA2 joints for cancer treatment
|
|
PE20260307A1
(es)
|
2023-06-14 |
2026-02-11 |
Astrazeneca Ab |
Degradadores de smarca2 y usos de estos
|
|
CN121969608A
(zh)
*
|
2023-06-23 |
2026-05-01 |
匹兹堡大学联邦系统高等教育 |
用于治疗HIV疾病的HIV-1 Nef靶向降解剂
|
|
EP4735451A1
(en)
|
2023-06-30 |
2026-05-06 |
Kumquat Biosciences Inc. |
Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
|
|
CN122206684A
(zh)
|
2023-06-30 |
2026-06-12 |
默克专利有限公司 |
用于kras蛋白降解的异双功能化合物
|
|
JP2026522894A
(ja)
|
2023-06-30 |
2026-07-09 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｋｒａｓ調節化合物
|
|
JP2026524477A
(ja)
|
2023-06-30 |
2026-07-22 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｋｒａｓの分解のためのヘテロ二官能性化合物
|
|
CN122161821A
(zh)
*
|
2023-07-12 |
2026-06-05 |
上海壹迪生物技术有限公司 |
氰基喹啉类靶向蛋白降解分子、其制备方法和应用
|
|
CN121568935A
(zh)
|
2023-07-26 |
2026-02-24 |
吉利德科学公司 |
Parp7抑制剂
|
|
AU2024297978A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
EP4763845A1
(en)
|
2023-08-17 |
2026-06-24 |
Haisco Pharmaceutical Group Co., Ltd. |
Cyano aromatic ring derivative and pharmaceutical use thereof
|
|
WO2025049555A1
(en)
|
2023-08-31 |
2025-03-06 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
EP4774280A1
(en)
|
2023-09-08 |
2026-07-15 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
CN119613374A
(zh)
*
|
2023-09-14 |
2025-03-14 |
中国科学院上海药物研究所 |
吲唑酮类化合物、其制备方法、药物组合物及其应用
|
|
AU2024344247A1
(en)
|
2023-09-19 |
2026-05-07 |
Kancure Pte. Ltd. |
Survivin-targeted compounds
|
|
IL326555A
(en)
|
2023-09-22 |
2026-04-01 |
Glaxosmithkline Ip Dev Ltd |
Androgen receptor protacs
|
|
TW202530189A
(zh)
|
2023-09-29 |
2025-08-01 |
日商第一三共股份有限公司 |
３－苯基丙基胺衍生物
|
|
KR20260085431A
(ko)
*
|
2023-10-02 |
2026-06-09 |
퍼듀 리서치 파운데이션 |
암 요법을 위한 shp2 분해제
|
|
WO2025085738A1
(en)
|
2023-10-18 |
2025-04-24 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
CN122228262A
(zh)
|
2023-11-02 |
2026-06-16 |
金橘生物科技公司 |
降解剂及其用途
|
|
WO2025096589A1
(en)
|
2023-11-03 |
2025-05-08 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025114875A1
(en)
*
|
2023-12-01 |
2025-06-05 |
Astrazeneca Ab |
Er degraders and uses thereof
|
|
US20250230168A1
(en)
|
2023-12-22 |
2025-07-17 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
AU2023477303A1
(en)
*
|
2023-12-22 |
2026-06-04 |
Captor Therapeutics S.A. |
Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target protein kinase c
|
|
WO2025179161A1
(en)
|
2024-02-21 |
2025-08-28 |
Innovo Therapeutics, Inc. |
Protein degrading compounds
|
|
WO2025188857A1
(en)
*
|
2024-03-05 |
2025-09-12 |
University Of Florida Research Foundation, Incorporated |
Hdac8 degraders and uses thereof
|
|
WO2025189056A1
(en)
|
2024-03-08 |
2025-09-12 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and their use in treating disease
|
|
WO2025212557A1
(en)
*
|
2024-04-01 |
2025-10-09 |
The Johns Hopkins University |
Delivery of aurora kinase inhibitors using nano-scale drug delivery platforms by covalent conjugation
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
TW202606657A
(zh)
*
|
2024-06-27 |
2026-02-16 |
南韓商韓美藥品股份有限公司 |
新型異雙功能蛋白質降解劑以及包含其的藥物組成物
|
|
US20260098049A1
(en)
|
2024-08-12 |
2026-04-09 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
CN119241498B
(zh)
*
|
2024-09-26 |
2026-04-07 |
天津科技大学 |
一种具有抗mash活性的acly靶向protac嵌合体、方法和应用
|
|
US20260130893A1
(en)
|
2024-10-21 |
2026-05-14 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2026120044A1
(en)
|
2024-12-04 |
2026-06-11 |
Astrazeneca Ab |
Smarca2 degraders and uses thereof
|
|
WO2026136515A1
(en)
|
2024-12-19 |
2026-06-25 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2026139448A1
(en)
|
2024-12-23 |
2026-07-02 |
Merck Patent Gmbh |
Heterobifunctional compounds for the degradation of kras protein
|